STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.

In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.

The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.

  • Headquartered in Madison, Wisconsin
  • Specializes in cancer screening and diagnostic tests
  • Flagship product: Cologuard, a noninvasive colorectal cancer screening test
  • Precision oncology products: Oncotype DX and OncoExTra
  • Active development of liquid biopsy tests
  • Exclusive intellectual property rights protecting screening technology

For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.

Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) revealed clinical validation data for its Oncodetect MRD test at ASCO GI 2025. The Alpha-CORRECT study demonstrated the test's effectiveness in detecting molecular residual disease in colorectal cancer patients, achieving 78% sensitivity post-surgery and 91% during surveillance, with specificities of 80% and 94% respectively.

The Beta-CORRECT study confirmed Oncodetect's prognostic value across stages II, III, and IV colon cancer and rectal cancer. The company plans to launch Oncodetect in Q2 2025 with Medicare coverage. Exact Sciences has established partnerships with NSABP and Flatiron Health to generate additional clinical evidence across multiple solid tumor types, including the CORRECT-I, CORRECT-II, and EXActDNA-003 studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) will present 11 abstracts at the ASCO GI Symposium in January 2025, showcasing significant advances in cancer screening and diagnostics. The company's Oncodetect™ molecular residual disease (MRD) test demonstrated strong performance in Stage III colon cancer patients, with 78% sensitivity post-surgery and 91% during surveillance, along with specificities of 80% and 94% respectively.

The data reveals high adherence rates for the Cologuard® test across different demographic groups: African Americans (62%), Hispanic population (63%), Asian population (69%), and 45-49-year-olds (65%). These rates significantly exceed the generally accepted FIT adherence of 42%. New modeling data indicates that screening with triennial Cologuard results in fewer colorectal cancer cases, lower treatment costs, and higher life years gained compared to blood-based tests at perfect adherence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) has announced preliminary Q4 2024 results, expecting total revenue of $713 million, up 10% year-over-year. The company's Screening segment revenue reached $553 million (+14%), while Precision Oncology revenue was $161 million (+0.4%).

For full-year 2024, Exact Sciences anticipates total revenue of $2.76 billion, representing a 10% increase from 2023. The company's Screening revenue grew 13% to $2.104 billion, and Precision Oncology revenue increased 4% to $655 million.

Looking ahead to 2025, the company plans to launch three new cancer tests: Cologuard Plus for colorectal cancer screening, Oncodetect for molecular residual disease, and Cancerguard for multi-cancer screening.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
Rhea-AI Summary

Exact Sciences (Nasdaq: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation followed by a Q&A session on Monday, January 13, 2025, at 1:30 p.m. ET.

Investors and interested parties can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences
-
Rhea-AI Summary

Exact Sciences (Nasdaq: EXAS), a cancer screening and diagnostic tests provider, has announced its management's participation in two upcoming investor conferences in Miami. The company will hold fireside chats at the Citi Global Healthcare Conference on December 3, 2024, at 8:45 a.m. ET, and at the Evercore HealthCONx Conference on December 4, 2024, at 7:30 a.m. ET. Investors can access the webcasts through the investor relations section of Exact Sciences' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
conferences
-
Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) will present 10 abstracts at the 2024 San Antonio Breast Cancer Symposium, showcasing their Precision Oncology portfolio. The presentations focus on the Oncotype DX Breast Recurrence Score® test, highlighting its effectiveness in guiding chemotherapy decisions and managing treatment costs.

New research from Japan demonstrates the test's cost-effectiveness, while other studies reveal that African American women typically show higher Recurrence Score® results compared to non-Hispanic White women, though with similar survival outcomes. The company aims to improve breast cancer care through personalized treatment planning and innovative solutions across all stages of cancer care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) presented three abstracts showcasing advancements in multi-cancer early detection (MCED) testing at the AACR Special Conference. A new study demonstrated that their multi-biomarker class approach improved cancer detection sensitivity, showing a 28% increase for stage I cancers and 12.5% for early-stage cancers at 98.5% specificity. New modeling data suggests that adding MCED testing to standard screening could reduce stage IV cancer incidence by 42% and cancer mortality by 17% over 10 years. Analysis from the DETECT-A study indicated MCED testing complements existing lung cancer screening without affecting adherence to standard care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

Exact Sciences reported Q3 2024 total revenue of $709 million, up 13% year-over-year, with Screening revenue of $545 million (+15%) and Precision Oncology revenue of $164 million (+5%). Despite recording a net loss of $38 million, the company achieved an adjusted EBITDA of $99 million with a 14% margin, representing a 500 basis point improvement. Operating cash flow reached $139 million with free cash flow of $113 million. Notable developments include FDA approval for Cologuard Plus™ test and promising results from their blood-based colorectal cancer screening test. However, the company revised down its full-year 2024 guidance for both revenue and adjusted EBITDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.48%
Tags
-
Rhea-AI Summary

Exact Sciences (Nasdaq: EXAS), a leader in cancer screening and diagnostic tests, has announced its upcoming participation in the Jefferies London Healthcare Conference. The company will host a fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET in London. Investors can access the webcast through the investor relations section of Exact Sciences' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
Rhea-AI Summary

Exact Sciences (NASDAQ: EXAS) will present modeling data at the American College of Gastroenterology Annual Meeting showcasing the Cologuard Plus™ test's effectiveness in colorectal cancer screening. The modeling data demonstrates that Cologuard Plus delivers the highest life-years gained with fewer colonoscopies among noninvasive screening strategies. The company will also present seven abstracts focusing on improving screening adherence rates, particularly in underserved populations. Studies show high adherence rates of 71.2% across insured individuals, with Spanish language support achieving 76.7% adherence. Implementation of reported strategies could potentially reduce the CRC screening gap by up to 10%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Exact Sciences (EXAS)?

The current stock price of Exact Sciences (EXAS) is $54.79 as of January 22, 2025.

What is the market cap of Exact Sciences (EXAS)?

The market cap of Exact Sciences (EXAS) is approximately 9.9B.

What is Exact Sciences Corp's main business?

Exact Sciences Corp specializes in molecular diagnostics, focusing on innovative cancer screening and diagnostic test products.

What is Cologuard?

Cologuard is a noninvasive stool-based DNA test designed to screen for colorectal cancer, integrated into major colorectal cancer screening guidelines.

Where is Exact Sciences Corp headquartered?

The company is headquartered in Madison, Wisconsin.

What are Oncotype DX and OncoExTra?

Oncotype DX is a suite of tissue-based genomic tests for cancer recurrence risk and chemotherapy benefit; OncoExTra is a liquid biopsy for comprehensive genomic profiling.

Is Exact Sciences developing any new tests?

Yes, the company is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

What is the significance of Exact Sciences' intellectual property?

Exact Sciences has exclusive intellectual property rights protecting its noninvasive molecular screening technology, reinforcing its market leadership.

Are Exact Sciences' products used internationally?

Yes, Exact Sciences provides cancer screening and diagnostic test products both in the United States and internationally.

How does Cologuard work?

Cologuard works by analyzing stool samples for DNA markers and blood that could indicate the presence of colorectal cancer or precancerous lesions.

What is the purpose of Oncotype DX tests?

Oncotype DX tests aim to estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy in breast and colon cancer patients.

Where can more information about Cologuard be found?

More information about Cologuard can be found at cologuardtest.com.
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

9.90B
182.39M
1.01%
101.55%
6.05%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MADISON